Granted Patent
B2
US 11,560,379 · App. 17/146,608 · Granted Jan 24, 2023
Octahydro fused azadecalin glucocorticoid receptor modulators
Inventors:
Hazel Hunt (Storrington, GB); Iain Walters (Nottingham, GB); Benoit Gourdet (Nottingham, GB)
Assignee:
Corcept Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides octahydro fused azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.
Claims (3)
1. The compound ((4aR,8aS)-1-(4-fluorophenyl)-6-((2-isopropyl-2H-1,2,3-triazol-4-yl)sulfonyl)-4,4a,5,6,7,8,8a,9-octahydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(thiazol-4-yl)methanone, having the formula
2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound having the formula:
3. A method of modulating a glucocorticoid receptor, comprising contacting a glucocorticoid receptor with a compound having the formula:
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 1, 2021
From: HUNT, HAZEL; WALTERS, IAIN; GOURDET, BENOIT
To: CORCEPT THERAPEUTICS, INC.
Reel/Frame 055093/0703 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 1, 2021
From: HUNT, HAZEL; WALTERS, IAIN; GOURDET, BENOIT
To: CORCEPT THERAPEUTICS, INC.
Reel/Frame 055093/0991 →
Continuity (8)
Provisional Application
61985035
· Apr 28, 2014
Provisional Application
61908333
· Nov 25, 2013
Cited By (4)